Patents by Inventor Michael Concino
Michael Concino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9932568Abstract: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders).Type: GrantFiled: November 2, 2015Date of Patent: April 3, 2018Assignee: Shire Human Genetic Therapies, Inc.Inventors: Paolo Martini, Michael Concino
-
Patent number: 9932377Abstract: The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.Type: GrantFiled: January 12, 2016Date of Patent: April 3, 2018Assignee: Shire Human Genetic Therapies, Inc.Inventors: Dennis Keefe, Michael Concino, Michael Heartlein, Serene Josiah, Bettina Strack-Logue
-
Publication number: 20160237129Abstract: The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.Type: ApplicationFiled: January 12, 2016Publication date: August 18, 2016Inventors: Dennis Keefe, Michael Concino, Michael Heartlein, Serene Josiah, Bettina Strack-Logue
-
Publication number: 20160152959Abstract: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders).Type: ApplicationFiled: November 2, 2015Publication date: June 2, 2016Inventors: Paolo Martini, Michael Concino
-
Patent number: 9260495Abstract: The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.Type: GrantFiled: June 15, 2012Date of Patent: February 16, 2016Assignee: Shire Human Genetic Therapies, Inc.Inventors: Dennis Keefe, Michael Concino, Michael Heartlein, Serene Josiah, Bettina Strack-Logue
-
Patent number: 9206235Abstract: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders).Type: GrantFiled: November 12, 2013Date of Patent: December 8, 2015Assignee: Shire Human Genetic Therapies, Inc.Inventors: Paolo Martini, Michael Concino
-
Patent number: 8945542Abstract: The present invention provides compositions and methods for effective treatment of a lysosomal acid lipase deficiency (LALD) disease, in particular, Wolman's disease and Cholesteryl Ester Storage Disease (CESD). Among other things, the present invention provides a method of treating developmental impairment or malnutrition in an individual suffering from a lysosomal acid lipase deficiency (LALD) disease, comprising administering to the individual a therapeutic effective amount of a lysosomal acid lipase.Type: GrantFiled: August 14, 2013Date of Patent: February 3, 2015Assignee: Synageva Biopharma Corp.Inventors: Michael Heartlein, Michael Concino, Paolo Martini, Muthuraman Meiyappan, Pericles Calias, Alla Romashko, Brian Pescatore, Lawrence Charnas, Jan Powell, Brian Felice, Nancy Savioli
-
Publication number: 20140187502Abstract: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders).Type: ApplicationFiled: November 12, 2013Publication date: July 3, 2014Applicant: Shire Human Genetic Therapies, Inc.Inventors: Paolo Martini, Michael Concino
-
Publication number: 20140135275Abstract: The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.Type: ApplicationFiled: June 15, 2012Publication date: May 15, 2014Applicant: Shire Human Genetic Therapies, Inc.Inventors: Dennis Keefe, Michael Concino, Michael Heartlein, Serene Josiah, Bettina Strack-Logue
-
Publication number: 20140044697Abstract: The present invention provides compositions and methods for effective treatment of a lysosomal acid lipase deficiency (LALD) disease, in particular, Wolman's disease and Cholesteryl Ester Storage Disease (CESD). Among other things, the present invention provides a method of treating developmental impairment or malnutrition in an individual suffering from a lysosomal acid lipase deficiency (LALD) disease, comprising administering to the individual a therapeutic effective amount of a lysosomal acid lipase.Type: ApplicationFiled: August 14, 2013Publication date: February 13, 2014Applicant: Synageva Biopharma Corp.Inventors: Michael Heartlein, Michael Concino, Paolo Martini, Muthuraman Meiyappan, Pericles Calias, Alla Romashko, Brian Pescatore, Lawrence Charnas, Jan Powell, Brian Felice, Nancy Savioli
-
Publication number: 20130330317Abstract: The present invention provides compositions and methods for effective treatment of a lysosomal acid lipase deficiency (LALD) disease, in particular, Wolman's disease and Cholesteryl Ester Storage Disease (CESD). Among other things, the present invention provides a method of treating a lysosomal acid lipase deficiency (LALD) disease, including administering to an individual suffering from or susceptible to the LALD disease a therapeutic effective amount of a lysosomal acid lipase periodically at an administration interval such that lipid level in liver, spleen and/or small intestine is reduced by at least 20% as compared to an untreated control.Type: ApplicationFiled: August 15, 2013Publication date: December 12, 2013Inventors: Gregory Grabowski, Hong Du, Michael Heartlein, Michael Concino, Paolo Martini, Muthuraman Meiyappan, Alla Romashko, Brian Pescatore, Lawrence Charnas
-
Patent number: 8580922Abstract: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders).Type: GrantFiled: March 2, 2012Date of Patent: November 12, 2013Assignee: Shire Human Genetic Therapies, Inc.Inventors: Paolo Martini, Michael Concino
-
Publication number: 20120232021Abstract: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders).Type: ApplicationFiled: March 2, 2012Publication date: September 13, 2012Inventors: Paolo Martini, Michael Concino